Trialbee: Transforming Clinical Trials by Making Participant Recruitment Efficient and Diverse

Clinical research has evolved enormously in the last decade, not only in the increase in the number of Clinical Trials but also in its complexity. The number of inclusion/exclusion criteria has increased by approximately 60%, and the number of variables to be studied in the trials by approximately 89%. This increase in complexity translates into an increase in the cost associated with the studies and questions about their sustainability.

In this sense, digitization and new technologies offer us an enormous opportunity to be more efficient, cut lags, and guarantee that innovative products reach the public.

Also, in a technological ecosystem, the patient is increasingly informed, wants, and must be part of decision-making. The opinion and experience of the patient as a participant in a clinical trial acquire fundamental importance in the design of the protocols and is positioned as one of the main axes in decision-making.

Recruiting patients into a study is one of the most complex and generally time-consuming phases in a trial. A Real-World-Data based triple qualification model developed by Trialbee brings an excellent opportunity to bring clinical trials to more patients.

In this regard, Trialbee is the flagbearer of innovation, specializing in patient matching and engagement. Based in Sweden, the company is a tech-enabled service organization offering a complete suite of software and services for clinical trial apps which are dedicated to accelerating the clinical trial process. The company’s services are fundamentally standard in pharmaceutical, biotechnology, Clinical Research Organizations (CRO), medical device companies, site management organizations, and public institutions.

Trialbee’s services optimize the arduous process of patient recruitment and patient engagement, before, and during a clinical trial. The platform has enabled a significant reduction in recruitment time compared to traditional recruitment methods. Furthermore, the following is a detailed account of how the Trialbee participant recruitment model works:

• Secure a segmented and targeted patient pool from the public domain inaccessible to hospitals or registries

• Digital outreach with Smart Patient Matching

• Ensure top-tier recruitment via pre-screening processes and professional, multilingual nurse practitioner recruitment interviews

• Enable retention of enrolled participants by engaging patients using an optimized platform

Sponsors, research institutions and clinics have a set of critical steps to follow during patient recruitment, where building trust and engagement with participants is necessary. For a successful clinical trial, maximum coordination between the study team and sites is integral for a highly desirable outcome. This is an aspect highly prioritized by Trialbee, as it equips institutions to build trust with patients using a patient-centric approach to clinical trial. Therefore, research institutions can understand and draw insights on targeted patients from a clinical perspective and set up meetings.

On the other hand, successful trials also highly depend on the proactive role of site staff, and it is the forefront priority of HCOs (HealthCare Organizations) to retain high-quality patient pools. Knowing this essential aspect, Trialbee’s digital recruitment and retention eliminate data variability and site loads with “better precision” and “statistical power”.

“Our recent engagements reflect how Trialbee is helping research communities to accelerate and predictably deliver high-quality recruitment for ongoing vaccine trials,” shared Lollo Eriksson, CEO of Trialbee.

The portal also brings the design of protocols based on real patient data through technological platforms that allow the analysis of the millions of data available in electronic Medical Records, guaranteeing confidentiality and data protection at all times.

During the ongoing Coronavirus pandemic, Trialbee plays an active role in promoting patient diversity for COVID-19 vaccine trials. “The need for diversity in clinical trials is more apparent and needed than ever to ensure that the people most at risk of contracting COVID-19 are represented, including ethnic minorities, socioeconomically disadvantaged groups, and individuals working in specific fields,” concluded Eriksson.